KR960022559A - 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl - Google Patents

슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl Download PDF

Info

Publication number
KR960022559A
KR960022559A KR1019950049536A KR19950049536A KR960022559A KR 960022559 A KR960022559 A KR 960022559A KR 1019950049536 A KR1019950049536 A KR 1019950049536A KR 19950049536 A KR19950049536 A KR 19950049536A KR 960022559 A KR960022559 A KR 960022559A
Authority
KR
South Korea
Prior art keywords
pseudomonas aeruginosa
protein
hybrid protein
carboxy terminal
membrane protein
Prior art date
Application number
KR1019950049536A
Other languages
English (en)
Inventor
크납 베른하르트
훈게러 클라우스-디터
브뢰커 미하엘
울리히 폰 슈펙트 베른트
돔다이 호르스트
Original Assignee
슈타인, 뵈슬
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈타인, 뵈슬, 베링베르케 아크티엔게젤샤프트 filed Critical 슈타인, 뵈슬
Publication of KR960022559A publication Critical patent/KR960022559A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 슈도모나스 에루지노사 외막 단백질 F(OprF)의 카복시-말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I(OprI)를 포함하는 하이브리드 단백질 및 상기 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체에 관한 것이다. 단백질 및 하이브리드 단백질 및 하이브리드 단백질에 대한 항체 모두는 실험 동물 또는 사람을 슈도모나스 에루지노사 감염으로부터 보호한다.

Description

슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피. 에루지노사(P. aeruginosa) 외막 단백질의 제작된 재조합 융합 단백질의 개략도이다.

Claims (8)

  1. 슈도모나스 에루지노사(Pseudomonas aeruginosa)외막 단백질 F의 카복시 말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I을 포함하는데, 이때 상기 카복시 말단 부분이 190번 350번 아미노산 서열을 포함하는 하이브리드 단백질.
  2. 제1항에 있어서, 상기 카복시 말단 부분이 190번 내지 342번 아미노산 서열인 하이브리드 단백질.
  3. 슈도모나스 에루지노사 외막 단백질 F의 카복시 말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I을 포함하는데, 이때 상기 카복시 말단 부분이 SEEI(212번 내지 240번 아미노산), SEE2(243번 내지 256번 아미노산), SEE3(285번 내지 298번 아미노산) 및 SEE4(332번 내지 350번 아미노산)로 이루어지는 그룹으로 부터 선택되는 하나 이상의 표면-노출된 B-세포 에피토프를 포함하는 하이브리드 단백질.
  4. 제1항 내지 제3항 중의 어느 한 항에 따른 하리브리드 단백질을 포함하는 백신.
  5. 제1항 내지 제3항 중의 어느 한 항에 따른 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체.
  6. 제5항에 따른 항체를 포함하는 백신.
  7. 제1항 내지 제3항 중 어느 한 항에 따른 하이브리드 단백질을 암호화하는 핵산.
  8. 진핵 세포 또는 원핵 세포에서 제7항에 따른 핵산을 발현시키는 것을 포함하는, 제1항 내지 제3항 중의 어느 한 항에 따른 하이브리드 단백질의 제조방법.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019950049536A 1994-12-16 1995-12-14 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl KR960022559A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94120023 1994-12-16
EP94120023.0 1994-12-16

Publications (1)

Publication Number Publication Date
KR960022559A true KR960022559A (ko) 1996-07-18

Family

ID=8216542

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950049536A KR960022559A (ko) 1994-12-16 1995-12-14 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl

Country Status (8)

Country Link
US (2) US5955090A (ko)
EP (1) EP0717106B1 (ko)
JP (2) JP3712244B2 (ko)
KR (1) KR960022559A (ko)
AT (1) ATE190657T1 (ko)
AU (1) AU4041995A (ko)
CA (1) CA2165401C (ko)
DE (1) DE69515613T2 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69616276T2 (de) * 1995-02-09 2002-12-12 Novartis Ag Verfahren zur produktion von proteinen
GB9701489D0 (en) * 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
KR100461710B1 (ko) * 1997-09-13 2005-09-28 씨제이 주식회사 신규한 녹농균 세포 외막 단백질 유전자 및 이를 이용한 녹농균 감염 예방용 백신 및 녹농균 감염증 치료제
GB9915044D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
EP1078988A1 (en) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas fusion protein vaccines
WO2001060404A2 (en) * 2000-02-18 2001-08-23 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
AU2002211201B2 (en) * 2000-11-02 2007-05-31 The National University Of Singapore aopB Gene, protein, homologs, fragments and variants thereof, and their use for cell surface display
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
WO2003042240A2 (en) * 2001-11-13 2003-05-22 Shire Biochem Inc. Polypeptides of pseudomonas aeruginosa
EP1790659B1 (en) 2001-11-13 2013-07-31 ID Biomedical Corporation Polypeptides of pseudomonas aeruginosa
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP2455390A1 (en) 2002-04-12 2012-05-23 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
WO2006105597A1 (en) 2005-04-08 2006-10-12 Melbourne Health Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
WO2007049770A1 (ja) 2005-10-28 2007-05-03 Meiji Seika Kaisha, Ltd. 緑膿菌の外膜タンパク質ｐａ５１５８
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CN101454446A (zh) 2006-03-30 2009-06-10 明治制果株式会社 绿脓杆菌的外膜蛋白pa0427
CA2691626A1 (en) * 2007-06-29 2009-01-08 Jiro Tanaka Pseudomonas aeruginosa-outer membrane protein pa4710
CN101970468A (zh) * 2007-12-25 2011-02-09 明治制果株式会社 绿脓杆菌的ⅲ型分泌系统构成蛋白质pa1698
WO2010107778A1 (en) 2009-03-18 2010-09-23 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
KR20130133212A (ko) 2010-12-23 2013-12-06 인터셀 오스트리아 아게 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
WO2012126879A1 (en) * 2011-03-18 2012-09-27 Intercell Ag Novel oprf/i fusion proteins, their preparation and use
RU2529359C2 (ru) * 2012-09-19 2014-09-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" Российской академии медицинских наук (ФГБУ "НИИВС им. И.И. Мечникова" РАМН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPA-OPRF-ETA, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa, ШТАММ Escherichia coli PA-OPRF-ETA - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa
LT2925355T (lt) 2012-11-30 2018-03-26 Glaxosmithkline Biologicals S.A. Pseudomonas antigenai ir antigenų deriniai
KR20170068456A (ko) * 2014-08-29 2017-06-19 소렌토 쎄라퓨틱스, 인코포레이티드 OprF 및 OprI에 결합하는 항체 치료제
WO2016193402A1 (en) * 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
EP3317295B1 (en) * 2015-07-04 2022-05-18 Evaxion Biotech A/S Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718591A1 (de) * 1987-06-03 1988-12-15 Behringwerke Ag Aeusseres membranprotein f von pseudomonas aeruginosa
DE3829616C2 (de) * 1988-09-01 1996-08-29 Behringwerke Ag Lipoprotein I (OMPI) von Pseudomonas aeruginosa
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
WO1993024636A1 (en) * 1992-05-29 1993-12-09 The University Of British Columbia Use of protein oprf for bacterial cell surface expression of oligopeptides

Also Published As

Publication number Publication date
DE69515613T2 (de) 2000-11-30
EP0717106B1 (en) 2000-03-15
JP3762779B2 (ja) 2006-04-05
JP2005097321A (ja) 2005-04-14
EP0717106A1 (en) 1996-06-19
DE69515613D1 (de) 2000-04-20
CA2165401C (en) 2010-05-11
CA2165401A1 (en) 1996-06-17
AU4041995A (en) 1996-06-27
US6300102B1 (en) 2001-10-09
US5955090A (en) 1999-09-21
JPH08245699A (ja) 1996-09-24
JP3712244B2 (ja) 2005-11-02
ATE190657T1 (de) 2000-04-15

Similar Documents

Publication Publication Date Title
KR960022559A (ko) 슈도모나스 에루지노사 막 단백질로부터 유도된 면역원성 하이브리드 단백질 OprF-Oprl
WO1995029193A3 (en) Melanoma antigens
KR910016343A (ko) 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
DE69833106D1 (de) Antigene fusionsproteine, die gal-alpha-1,3-gal-epitope enthalten.
CY1111831T1 (el) Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο
KR950702635A (ko) 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
NZ507378A (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
Yoshimura et al. Purification and properties of a 75-kilodalton major protein, an immunodominant surface antigen, from the oral anaerobe Bacteroides gingivalis
FR2669338B1 (ko)
DE69419966T2 (de) Impstoff gegen Streptococcus suis-Infektion
DE69515340D1 (de) Impfstoff gegen mycobakterielle infektionen
Watts et al. Mapping of the antigenic determinants of Pseudomonas aeruginosa PAK polar pili
KR930012827A (ko) 항 사람 IgE 모노클로날 항체
DE68923006D1 (de) Fusionsproteine der untereinheit b von choleratoxin und eines heterologen antigens und dafür kodierende rekombinante nukleinsäure.
MX9801089A (es) Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna.
KR900004935A (ko) 슈도 모나즈 아에루기노사의 지질단백질 i(ompi)
RU2206610C2 (ru) Выделенная и очищенная молекула нуклеиновой кислоты (варианты), плазмидный вектор, выделенный и очищенный высокомолекулярный белок (hmw) нетипичных haemophilus, конъюгат, синтетический пептид
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
DE59710668D1 (de) Monoklonale antikörper gegen das epitop ypydvpdya, verfahren zu deren herstellung und ihre verwendung

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid